Represented Prometheus Laboratories, Inc. owner of an Orange Book listed branded drug, Lotronex (alosetron hydrochloride), indicated for women with severe Irritable Bowel Syndrome. Prometheus Labs bought the franchise from GSK several years ago, however US Patent No. 6,284,770 drawn to a method for treatment was not listed in the Orange Book. A reexamination strategy was devised to ensure patentability of the claims that covered the indication. After an initial PTO action denying the reexamination request, a petition was filed citing further relevant facts. Thereafter, the petition was granted. After successful prosecution of amended claims, a reexamination certificate issued providing valid patent coverage for Lotronex. The reexamined patent is now listed in the Orange Book.

Experience Center

Match our Experience to Your Needs

Experience Highlights

In re Southwest Hospital
Represented creditors' committee and then plan trustee of Southwest Hospital and Medical Center Inc. in connection with the sale of an Atlanta more
Joint venture of gaming and resort company
Representation of gaming and resort company in theme park development joint venture. more
Technology license for a networking equipment company
Represented networking equipment company in technology license. more
Largest proposed OSHA fine in North Carolina history for HoltraChem Manufacturing Company
Represented the HoltraChem Manufacturing Co. in the largest Occupational Safety and Health Administration (OSHA) fine in North Carolina history. more